An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAT2505
U.S. Govt. ID: NCT04613492
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if two drugs, MEDI9253 and durvalumab, will be safe for the treatment of solid tumors. MEDI9253 and durvalumab are types of cancer therapies that try to boost the immune system to fight cancer. MEDI9253 is an oncolytic virus (a virus that infects and breaks down cancer cells but not normal cells) and may also help the immune system recognize cancer cells to destroy. MEDI9253 is an experimental drug. This means that is has not been approved for treatment by any regulatory authority that regulates new medicines, such as the U.S. Food and Drug Administration (FDA). Cancers include colorectal cancer, kidney cancer, and melanoma.
Investigator
Ryan Moy, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with colorectal cancer, kidney cancer, or melanoma? Yes No
Do you have a life expectancy of at least 12 weeks? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE